Rep. April McClain Delaney Buys Labcorp Holdings Inc. (NYSE:LH) Shares

Representative April McClain Delaney (D-Maryland) recently bought shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on November 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Labcorp stock on October 29th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Teledyne Technologies (NYSE:TDY) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/29/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/29/2025.
• Sold $1,001 – $15,000 in shares of Middleby (NASDAQ:MIDD) on 10/22/2025.
• Purchased $15,001 – $50,000 in shares of Nasdaq (NASDAQ:NDAQ) on 10/22/2025.
• Purchased $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 10/22/2025.

Labcorp Price Performance

Shares of LH opened at $245.96 on Friday. Labcorp Holdings Inc. has a one year low of $209.38 and a one year high of $293.72. The stock’s fifty day moving average is $274.80 and its 200-day moving average is $261.87. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.55. The firm has a market capitalization of $20.39 billion, a price-to-earnings ratio of 24.16, a price-to-earnings-growth ratio of 1.59 and a beta of 0.91.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $4.18 earnings per share for the quarter, topping the consensus estimate of $4.13 by $0.05. The business had revenue of $3.56 billion during the quarter, compared to the consensus estimate of $3.56 billion. Labcorp had a net margin of 6.21% and a return on equity of 15.85%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.50 earnings per share. Labcorp has set its FY 2025 guidance at 16.150-16.500 EPS. Equities analysts anticipate that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Stockholders of record on Wednesday, November 26th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $2.88 annualized dividend and a dividend yield of 1.2%. Labcorp’s dividend payout ratio is presently 28.29%.

Insiders Place Their Bets

In related news, EVP Der Vaart Sandra D. Van sold 3,903 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $271.42, for a total value of $1,059,352.26. Following the completion of the sale, the executive vice president owned 2,274 shares in the company, valued at approximately $617,209.08. This represents a 63.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richelle P. Parham sold 7,009 shares of the firm’s stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $254.28, for a total transaction of $1,782,248.52. Following the completion of the transaction, the director directly owned 2,469 shares of the company’s stock, valued at $627,817.32. This represents a 73.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 16,555 shares of company stock worth $4,347,040 over the last ninety days. 0.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Labcorp

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank acquired a new stake in shares of Labcorp during the second quarter worth $263,070,000. Lazard Asset Management LLC boosted its position in shares of Labcorp by 224.1% in the 2nd quarter. Lazard Asset Management LLC now owns 989,433 shares of the medical research company’s stock valued at $259,734,000 after purchasing an additional 684,153 shares during the period. Select Equity Group L.P. increased its stake in Labcorp by 39.1% in the 1st quarter. Select Equity Group L.P. now owns 2,220,056 shares of the medical research company’s stock worth $516,696,000 after purchasing an additional 624,099 shares in the last quarter. Nordea Investment Management AB raised its holdings in Labcorp by 28.2% during the 2nd quarter. Nordea Investment Management AB now owns 1,829,039 shares of the medical research company’s stock worth $476,995,000 after buying an additional 401,808 shares during the period. Finally, Invesco Ltd. raised its holdings in Labcorp by 28.9% during the 1st quarter. Invesco Ltd. now owns 1,421,112 shares of the medical research company’s stock worth $330,750,000 after buying an additional 318,865 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analyst Ratings Changes

LH has been the subject of several recent analyst reports. HSBC cut shares of Labcorp from a “buy” rating to a “hold” rating and set a $260.00 price objective for the company. in a report on Thursday, July 10th. Morgan Stanley increased their price target on Labcorp from $283.00 to $306.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Truist Financial set a $320.00 price target on Labcorp in a research report on Tuesday, October 14th. Hsbc Global Res downgraded Labcorp from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Finally, Robert W. Baird set a $304.00 target price on Labcorp in a research note on Wednesday, October 29th. Eleven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $295.54.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.